A new tuberculosis (TB) test developed by the Translational Genomics Research Institute (TGen) will be marketed and distributed by Advanced Biological Laboratories (ABL) under the terms of a licensing agreement reached between the two companies this week.
The test — DeepCheck-TB — is currently only usable in research, though ABL want to oversee a compact, portable and economical diagnostic model for global physician use. Its creators believe it has the potential for major action against a disease that infects nearly one-fourth of the world’s population.
“Significantly, our TB assay technology holds the potential to provide doctors — even those in relatively rural settings — a quick and economical way to accurately determine the exact drugs that can and can’t be used for each patient,” David Engelthaler, co-director of TGen’s Pathogen and Microbiome Division, said.
Its creators have said that tests utilizing DeekCheck-TB can be completed within 2-3 days and can identify drug-resistance strands of TB. Current tests come with no such guarantee and can take as long as nine weeks to complete. Given that drug-resistant strains have been mutating into use around the world, that fact becomes an ever-greater concern for health experts.
ABL, a Luxembourg-based company, wants to see the new test distributed worldwide.
Members of Congress recently paraded a mix of recommended updates to benefit military service members…
The ByteDance-owned TikTok faces an uphill battle in the United States after President Joe Biden…
Promising to grow space for integrating and delivering on critical defense programs by more than…
In unsealing a 13-page indictment this week, the U.S. Department of Justice (DOJ) revealed charges…
A bill targeting the illicit fentanyl supply chain, the Fentanyl Eradication and Narcotics Deterrence (FEND)…
In order to move the state closer to federal standards and allow reporting of local…
This website uses cookies.